Follow this preprint
Gaining Control of Combination Cancer Treatment Risk by Incorporating Cost and Value Data into the Drug Selection Process at the Point–of–Care
Richard L. Nicholas
doi: https://doi.org/10.1101/2022.02.13.22270914
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Richard L. Nicholas
1TPA Network Research Consortium
Posted March 06, 2022.
Gaining Control of Combination Cancer Treatment Risk by Incorporating Cost and Value Data into the Drug Selection Process at the Point–of–Care
Richard L. Nicholas
medRxiv 2022.02.13.22270914; doi: https://doi.org/10.1101/2022.02.13.22270914
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Subject Areas
- Addiction Medicine (407)
- Allergy and Immunology (718)
- Anesthesia (213)
- Cardiovascular Medicine (3030)
- Dermatology (256)
- Emergency Medicine (453)
- Epidemiology (12949)
- Forensic Medicine (12)
- Gastroenterology (845)
- Genetic and Genomic Medicine (4755)
- Geriatric Medicine (439)
- Health Economics (745)
- Health Informatics (3020)
- Health Policy (1091)
- Hematology (405)
- HIV/AIDS (950)
- Medical Education (448)
- Medical Ethics (118)
- Nephrology (488)
- Neurology (4532)
- Nursing (241)
- Nutrition (669)
- Oncology (2353)
- Ophthalmology (665)
- Orthopedics (262)
- Otolaryngology (332)
- Pain Medicine (294)
- Palliative Medicine (85)
- Pathology (511)
- Pediatrics (1226)
- Primary Care Research (513)
- Public and Global Health (7118)
- Radiology and Imaging (1579)
- Respiratory Medicine (939)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (502)
- Toxicology (63)
- Transplantation (217)
- Urology (187)